345-94-8

Basic information

• Product Name: 2-bromo-1-(4-fluorophenyl)propan-1-one
• Synonyms: 2-bromo-1-(4-fluorophenyl)propan-1-one;2-BroMo-1-(4-fluorophenyl)-1-propanone, 98%;1-Propanone, 2-bromo-1-(4-fluorophenyl)-
• CAS NO: 345-94-8
• Molecular Formula: C₉H₈BrFO
• Molecular Weight: 231.0616232
• EINECS: 1533716-785-6
• Mol File: 345-94-8.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 260.8 °C at 760 mmHg
• Flash Point: 111.5 °C
• Appearance: /Solid
• Density: 1.488 g/cm³
• Vapor Pressure: 0.012mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: Amber Vial, Refrigerator
• Solubility: Chloroform (Sparingly)
• Stability: Light Sensitive
• CAS DataBase Reference: 2-bromo-1-(4-fluorophenyl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-(4-fluorophenyl)propan-1-one(345-94-8)
• EPA Substance Registry System: 2-bromo-1-(4-fluorophenyl)propan-1-one(345-94-8)

Safety Data

• Hazardous Substances Data: 345-94-8(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(4-fluorophenyl)propan-1-one is a chemical compound that belongs to the class of organic compounds known as benzene and substituted derivatives. It is composed of carbon, hydrogen, fluorine and bromine atoms. 2-bromo-1-(4-fluorophenyl)propan-1-one is primarily used in the preparation of several types of pharmaceuticals and in chemical research as an intermediary substance. Its application is primarily professional, often in a laboratory setting. Structural characteristics include a fluorine-substituted phenyl group, a bromine atom, and a ketone functional group. As with all chemicals, proper safety measures, including the use of personal protective equipment and safe disposal methods, should be followed when handling.

InChI:InChI=1/C9H8BrFO/c1-6(10)9(12)7-2-4-8(11)5-3-7/h2-6H,1H3

Upstream product

• 456-03-1 1-(4-fluorophenyl)propan-1-one 
• 462-06-6 fluorobenzene 
• 563-76-8 α-bromopropionyl bromide 
• 1194-02-1 4-fluorobenzonitrile 
• 93-55-0 1-phenyl-propan-1-one 

Downstream Products

• 387-29-1 N-[2-(4-fluoro-phenyl)-1-methyl-2-oxo-ethyl]-phthalimide 
• 118887-69-7 2-Bromo-1-(4-fluoro-phenyl)-propan-1-ol 
• 211242-52-3 2-N,N-dibenzylamino-1-(4-fluorophenyl)-1-propanone 
• 111000-51-2 2-{4-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]-1-piperidyl}-1-(4-fluorophenyl)-1-propanone 
• 1219095-61-0 3-(3,5-dimethoxyphenyl)-4-(4-fluorophenyl)-5-hydroxy-5-methyl-2(5H)-furanone 
• 1321959-87-8 4-(4-fluorophenyl)-N-(3,5-dimethylphenyl)-5-methylthiazol-2-amine 
• 46083-40-3 (1RS,2RS)-2-amino-1-(4-fluorophenyl)propan-1-ol 
• 198480-08-9 5-(benzyloxy)-1-[[4-(2-bromoethoxy)phenyl]methyl]-2-(4-fluorophenyl)-3-methyl-1H-indole 

Relevant articles and documents

Structural spectroscopic study of enantiomerically pure synthetic cathinones and their major metabolites

New psychoactive substances (NPSs) have become a popular alternative to illicit drugs of abuse. However, to determine their metabolic pathways in the human organism, a detailed knowledge of their structure is crucial. Here, we present a comprehensive spectroscopic structural study of synthetic cathinones (clephedrone, flephedrone, and brephedrone) and their major human metabolites, desmethyl derivatives. Chiral high-performance liquid chromatography was utilized to obtain the individual enantiomers of the parent synthetic cathinones and their assumed major metabolites synthesized de novo. The developed chromatographic method made it possible to obtain the target optically pure substances on a multimilligram scale. Electronic and vibrational circular dichroism, combined with infrared and ultraviolet spectroscopy and supported by DFT calculations, were used to determine their absolute configuration and the chiroptical methods to elucidate their molecular structure in detail. Two stable conformers of each substance were found in aqueous solution. Their relative abundances were estimated based on the Boltzmann distribution and the population weighted spectra were obtained. Very good agreement was achieved between the experimental and simulated spectra, enabling the 3D structures of the studied substances to be determined in aqueous solution. This journal is

Design, synthesis and broad-spectrum Bcr-Abl inhibitory activity of novel thiazolamide-benzamide derivatives

Bcr-Abl plays an important role in the pathogenesis and development of chronic myeloid leukemia (CML). But Bcr-Abl is prone to mutation, so it increases the difficulty of clinical treatment. Therefore, it is crucial to design a new class of broad-spectrum Bcr-Abl inhibitors. Herein, forty novel thiazolamide-benzamide derivatives were synthesized and evaluated their broad-spectrum Bcr-Abl inhibitory activities. The newly synthesized compounds were characterized by using spectrum data (1H NMR, APCI-MS and IR) and elemental analysis. The protein kinase results indicated that eight compounds (3a, 3e, 3m, 3n, 3p, 4c, 4f, 4g) showed high activities to wild-type and T315I mutation. The most potent compound 3m exhibited an Abl IC50 value as low as 1.273 μM and showed inhibition to the T315I mutant with IC50 value 39.89 μM. 3m could prove to be a new promising lead compound for the further development of broad-spectrum Bcr-Abl inhibitors to overcome clinical acquired resistance.

INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.